{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:01:25Z","timestamp":1776888085507,"version":"3.51.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T00:00:00Z","timestamp":1345075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00210-012-0791-6","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T23:21:05Z","timestamp":1360970465000},"page":"1117-1125","source":"Crossref","is-referenced-by-count":15,"title":["Antihypertrophic effects of combined inhibition of the renin\u2013angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure"],"prefix":"10.1007","volume":"385","author":[{"given":"Christoph","family":"Birner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coskun","family":"Ulucan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Bratfisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"G\u00f6tz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Dietl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Schweda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter A.","family":"Riegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Luchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,16]]},"reference":[{"issue":"2","key":"791_CR1","doi-asserted-by":"crossref","first-page":"H722","DOI":"10.1152\/ajpheart.00737.2004","volume":"288","author":"ZA Abassi","year":"2005","unstructured":"Abassi ZA, Yahia A, Zeid S, Karram T, Golomb E, Winaver J et al (2005) Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure. Am J Physiol Heart Circ Physiol 288(2):H722\u2013H728","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"791_CR2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1365-2125.2000.00257.x","volume":"50","author":"M Bani","year":"2000","unstructured":"Bani M, Colantoni A, Guillaume M, Macchi F, Moroni G, Persiani S (2000) A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers. Br J Clin Pharmacol 50(4):338\u2013349","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"791_CR3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cyto.2007.08.009","volume":"40","author":"CM Birner","year":"2007","unstructured":"Birner CM, Ulucan C, Fredersdorf S, Rihm M, L\u00f6wel H, Stritzke J et al (2007) Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: superiority of BNP. Cytokine 40(2):89\u201397","journal-title":"Cytokine"},{"issue":"5","key":"791_CR4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00210-011-0723-x","volume":"385","author":"C Birner","year":"2012","unstructured":"Birner C, Husser O, Jeron A, Rihm M, Fredersdorf S, Resch M et al (2012a) Differential expression of potassium channels and abnormal conduction in experimental tachycardia-induced heart failure. Naunyn Schmiedebergs Arch Pharmacol 385(5):473\u2013480","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol"},{"key":"791_CR5","doi-asserted-by":"crossref","unstructured":"Birner C, Dietl A, Deutzmann R, Schmid P, Jungbauer C, Resch M et al (2012) Inter- and intraventricular proteomic profiling implies mitochondrial dysfunction in tachycardia-induced heart failure. J Card Fail 18:660\u2013673","DOI":"10.1016\/j.cardfail.2012.06.418"},{"issue":"4","key":"791_CR6","doi-asserted-by":"crossref","first-page":"H1686","DOI":"10.1152\/ajpheart.00384.2005","volume":"290","author":"Y Cha","year":"2006","unstructured":"Cha Y, Dzeja PP, Redfield MM, Shen WK, Terzic A (2006) Bioenergetic protection of failing atrial and ventricular myocardium by vasopeptidase inhibitor omapatrilat. Am J Physiol Heart Circ Physiol 290(4):H1686\u2013H1692","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"791_CR7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/13543784.2011.556617","volume":"20","author":"F Cuculi","year":"2011","unstructured":"Cuculi F, Erne P (2011) Combined neutral endopeptidase inhibitors. Expert Opin Investig Drugs 20(4):457\u2013463","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"791_CR8","first-page":"824","volume":"231","author":"P Daull","year":"2006","unstructured":"Daull P, Blouin A, Beaudoin M, Gadbois S, Belleville K, Cayer J et al (2006) The hemodynamic and metabolic profiles of Zucker diabetic fatty rats treated with a single molecule triple vasopeptidase inhibitor, CGS 35601. Exp Biol Med (Maywood) 231(6):824\u2013829","journal-title":"Exp Biol Med (Maywood)"},{"issue":"7","key":"791_CR9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00125-003-1121-9","volume":"46","author":"BJ Davis","year":"2003","unstructured":"Davis BJ, Johnston CI, Burrell LM, Burns WC, Kubota E, Cao Z et al (2003) Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 46(7):961\u2013971","journal-title":"Diabetologia"},{"issue":"10","key":"791_CR10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"K Dickstein","year":"2008","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA et al (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10(10):933\u2013989","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"791_CR11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/1071-9164(95)90029-2","volume":"1","author":"D Elsner","year":"1995","unstructured":"Elsner D, Riegger GA (1995a) Experimental heart failure produced by rapid ventricular pacing in the dog. J Card Fail 1(3):229\u2013247","journal-title":"J Card Fail"},{"issue":"3","key":"791_CR12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00001573-199505000-00004","volume":"10","author":"D Elsner","year":"1995","unstructured":"Elsner D, Riegger GA (1995b) Characteristics and clinical relevance of animal models of heart failure. Curr Opin Cardiol 10(3):253\u2013259","journal-title":"Curr Opin Cardiol"},{"issue":"6","key":"791_CR13","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1161\/01.HYP.0000168944.29525.da","volume":"45","author":"N Emoto","year":"2005","unstructured":"Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY et al (2005) Dual ECE\/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 45(6):1145\u20131152","journal-title":"Hypertension"},{"issue":"4","key":"791_CR14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FJC.0b013e318210fc7e","volume":"57","author":"LG Hegde","year":"2011","unstructured":"Hegde LG, Yu C, Renner T, Thibodeaux H, Armstrong SR, Park T et al (2011) Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol 57(4):495\u2013504","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"791_CR15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"SA Hunt","year":"2005","unstructured":"Hunt SA (2005) ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46(6):e1\u2013e82","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"791_CR16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.jhh.1002009","volume":"20","author":"AG Johnson","year":"2006","unstructured":"Johnson AG, Pearce GL, Danoff TM (2006) A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE\/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients. J Hum Hypertens 20(7):496\u2013503","journal-title":"J Hum Hypertens"},{"issue":"2","key":"791_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E (2004) Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17(2):103\u2013111","journal-title":"Am J Hypertens"},{"issue":"2","key":"791_CR18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1210\/jc.84.2.723","volume":"84","author":"JG Lainchbury","year":"1999","unstructured":"Lainchbury JG, Richards AM, Nicholls MG, Espiner EA, Yandle TG (1999) Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment. J Clin Endocrinol Metab 84(2):723\u2013729","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"791_CR19","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S0735-1097(02)01837-5","volume":"39","author":"N Lapointe","year":"2002","unstructured":"Lapointe N, Blais C, Adam A, Parker T, Sirois MG, Gosselin H et al (2002) Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol 39(10):1692\u20131698","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"791_CR20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1054\/jcaf.2002.0805288","volume":"8","author":"R Latini","year":"2002","unstructured":"Latini R, Masson S, de Angelis N, Anand I (2002) Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. J Card Fail 8(5):288\u2013299","journal-title":"J Card Fail"},{"issue":"3","key":"791_CR21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3317\/jraas.2006.025","volume":"7","author":"W Linz","year":"2006","unstructured":"Linz W, Sch\u00e4fer S, Afkham F, Gerl M, Schmidts H, R\u00fctten H (2006) Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst 7(3):155\u2013161","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"3","key":"791_CR22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.HYP.28.3.472","volume":"28","author":"A Luchner","year":"1996","unstructured":"Luchner A, Stevens TL, Borgeson DD, Redfield MM, Bailey JE, Sandberg SM et al (1996) Angiotensin II in the evolution of experimental heart failure. Hypertension 28(3):472\u2013477","journal-title":"Hypertension"},{"issue":"5 Pt 2","key":"791_CR23","first-page":"H1684","volume":"274","author":"A Luchner","year":"1998","unstructured":"Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG et al (1998) Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274(5 Pt 2):H1684\u2013H1689","journal-title":"Am J Physiol"},{"issue":"3","key":"791_CR24","doi-asserted-by":"crossref","first-page":"R974","DOI":"10.1152\/ajpregu.2000.279.3.R974","volume":"279","author":"A Luchner","year":"2000","unstructured":"Luchner A, Jougasaki M, Friedrich E, Borgeson DD, Stevens TL, Redfield MM et al (2000) Activation of cardiorenal and pulmonary tissue endothelin-1 in experimental heart failure. Am J Physiol Regul Integr Comp Physiol 279(3):R974\u2013R979","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"3","key":"791_CR25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0008-6363(01)00316-9","volume":"51","author":"A Luchner","year":"2001","unstructured":"Luchner A, Muders F, Dietl O, Friedrich E, Blumberg F, Protter AA et al (2001) Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction. Cardiovasc Res 51(3):601\u2013607","journal-title":"Cardiovasc Res"},{"issue":"1\u20132","key":"791_CR26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1027337601863","volume":"254","author":"T Maki","year":"2003","unstructured":"Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S (2003a) Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure. Mol Cell Biochem 254(1\u20132):265\u2013273","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"791_CR27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1124\/jpet.102.042747","volume":"305","author":"T Maki","year":"2003","unstructured":"Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S (2003b) Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation. J Pharmacol Exp Ther 305(1):97\u2013105","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"791_CR28","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1111\/j.1523-1755.2005.00269.x","volume":"67","author":"FL Martin","year":"2005","unstructured":"Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM et al (2005) Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int 67(5):1723\u20131730","journal-title":"Kidney Int"},{"issue":"3","key":"791_CR29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1020644304771","volume":"16","author":"T Mishima","year":"2002","unstructured":"Mishima T, Tanimura M, Suzuki G, Todor A, Sharov VG, Tanhehco EJ et al (2002) Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure. Cardiovasc Drugs Ther 16(3):209\u2013214","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"791_CR30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0008-6363(99)00032-2","volume":"42","author":"GW Moe","year":"1999","unstructured":"Moe GW, Armstrong P (1999) Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res 42(3):591\u2013599","journal-title":"Cardiovasc Res"},{"issue":"12","key":"791_CR31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cpcardiol.2004.07.002","volume":"29","author":"VK Munagala","year":"2004","unstructured":"Munagala VK, Burnett JC, Redfield MM (2004) The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 29(12):707\u2013769","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"791_CR32","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1440-1681.1992.tb00477.x","volume":"19","author":"Y Murohara","year":"1992","unstructured":"Murohara Y, Johnston CI (1992) Effect of neutral endopeptidase inhibitor in rats with congestive heart failure. Clin Exp Pharmacol Physiol 19(5):380\u2013383","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"10","key":"791_CR33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.amjhyper.2006.02.013","volume":"19","author":"T Nishikimi","year":"2006","unstructured":"Nishikimi T, Mori Y, Ishimura K, Ishikawa Y, Koshikawa S, Akimoto K et al (2006) Chronic effect of combined treatment with omapatrilat and adrenomedullin on the progression of heart failure in rats. Am J Hypertens 19(10):1039\u20131048","journal-title":"Am J Hypertens"},{"issue":"8","key":"791_CR34","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J et al (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106(8):920\u2013926","journal-title":"Circulation"},{"issue":"25","key":"791_CR35","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.2174\/138161205774424708","volume":"11","author":"T Quaschning","year":"2005","unstructured":"Quaschning T (2005) Vasopeptidase inhibition for blood pressure control: emerging experience. Curr Pharm Des 11(25):3293\u20133299","journal-title":"Curr Pharm Des"},{"issue":"1","key":"791_CR36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11906-002-0057-7","volume":"4","author":"T Quaschning","year":"2002","unstructured":"Quaschning T, Ruschitzka F, L\u00fcscher TF (2002) Vasopeptidase inhibition: effective blood pressure control for vascular protection. Curr Hypertens Rep 4(1):78\u201384","journal-title":"Curr Hypertens Rep"},{"key":"791_CR37","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1046\/j.1523-1755.63.s84.35.x","volume":"84","author":"T Quaschning","year":"2003","unstructured":"Quaschning T, Galle J, Wanner C (2003) Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction. Kidney Int Suppl 84:S54\u2013S57","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"791_CR38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/01.HYP.0000030178.90322.11","volume":"40","author":"F Regamey","year":"2002","unstructured":"Regamey F, Maillard M, Nussberger J, Brunner HR, Burnier M (2002) Renal hemodynamic and natriuretic effects of concomitant angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension 40(3):266\u2013272","journal-title":"Hypertension"},{"issue":"1","key":"791_CR39","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/CIR.0b013e31823ac046","volume":"125","author":"VL Roger","year":"2012","unstructured":"Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB et al (2012) Heart disease and stroke statistics\u20132012 update: a report from the American Heart Association. Circulation 125(1):e2\u2013e220","journal-title":"Circulation"},{"issue":"3","key":"791_CR40","first-page":"191","volume":"46","author":"BP Roques","year":"1998","unstructured":"Roques BP (1998) Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives. Pathol Biol 46(3):191\u2013200","journal-title":"Pathol Biol"},{"issue":"9722","key":"791_CR41","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP (2010) Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375(9722):1255\u20131266","journal-title":"Lancet"},{"issue":"3","key":"791_CR42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00210-008-0361-0","volume":"379","author":"H Schneider","year":"2009","unstructured":"Schneider H, Husser O, Rihm M, Fredersdorf S, Birner C, Dhein S et al (2009) Safety of the novel atrial-selective K+ -channel blocker AVE0118 in experimental heart failure. Naunyn Schmiedebergs Arch Pharmacol 379(3):225\u2013232","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol"},{"key":"791_CR43","doi-asserted-by":"crossref","unstructured":"Spinale FG, Eble DM, Mukherjee R, Johnson WS, Walker JD (1994) Left ventricular and myocyte structure and function following chronic ventricular tachycardia in rabbits. Basic Res Cardiol 89(5):456\u2013467","DOI":"10.1007\/BF00788282"},{"issue":"8","key":"791_CR44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0895-7061(96)00099-4","volume":"9","author":"JP Stasch","year":"1996","unstructured":"Stasch JP, Hirth-Dietrich C, Ganten D, Wegner M (1996) Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am J Hypertens 9(8):795\u2013802","journal-title":"Am J Hypertens"},{"issue":"7","key":"791_CR45","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00059-002-2420-5","volume":"27","author":"A Staudt","year":"2002","unstructured":"Staudt A, Landsberger M, Staudt Y, Felix SB (2002) Die Rolle der Zytokine bei der Herzinsuffizienz. Herz 27(7):691\u2013698","journal-title":"Herz"},{"issue":"1","key":"791_CR46","first-page":"83","volume":"10","author":"J Xu","year":"2004","unstructured":"Xu J, Carretero OA, Liu Y, Yang F, Shesely EG, Oja-Tebbe N et al (2004) Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail 10(1):83\u201389","journal-title":"J Card Fail"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-012-0791-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-012-0791-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-012-0791-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T20:23:17Z","timestamp":1562703797000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-012-0791-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,16]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["791"],"URL":"https:\/\/doi.org\/10.1007\/s00210-012-0791-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,16]]}}}